NICE Recommends Amgen’s Sotorasib for Nonsmall-Cell Lung Cancer

The UK’s National Institute for Health and Care Excellence (NICE) has recommended that the National Health Service (NHS) offer Amgen’s Lumykras (sotorasib) for patients with nonsmall-cell lung cancer (NSCLC) who have received at least one prior line of therapy.

Supporting trial data indicated that sotorasib, which is the first targeted treatment for the KRAS G12C gene mutation, increases the time before cancer progresses and how long people live compared with current treatments, NICE said.

Lumykras was the first treatment to be evaluated through a new UK expedited review process launched in January — the Innovative Licensing and Access Pathway (ILAP) — and receive a positive opinion from NICE.

The FDA approved the potential blockbuster drug for the same indication in May 2021. It is sold in the U.S. as Lumakras.